Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ZCC
|
|||
| Former ID |
DIB013327
|
|||
| Drug Name |
MTC-896
|
|||
| Synonyms |
MC-5 antagonists (dermatological disease), Mimetica
Click to Show/Hide
|
|||
| Indication | Seborrhea [ICD-11: ED91.2; ICD-10: L73.8] | Phase 2 | [1] | |
| Company |
Mimetica Pty Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor 5 (MC5R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02395549) A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Avarx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.